Grepafloxacin: pharmacokinetics and tissue penetration

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

Grepafloxacin: microbiological properties

Approach to diagnosis of infective endocarditis

The changing epidemiology of severe infections in the ICU

Herpes zoster in non-hospitalized children

Antimicrobial Activity of SCH 27899, Oligosaccharide Member of the Everninomycin Class with a Wide Gram-Positive Spectrum Ronald N. Jones, M.D., Mary.

Evolution of extended-spectrum β-lactamases by mutation

Atypical respiratory pathogens

Hydatid disease Clinical Microbiology and Infection

Didier Guillemot, Claude Carbon Clinical Microbiology and Infection

Link between intracellular pathogens and cardiovascular diseases

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription B. Maraha, M. Bonten, H. Fiolet,

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

Structure of grepafloxacin relative to activity and safety profile

D.E. Low Clinical Microbiology and Infection

Vector control: a cornerstone in the malaria elimination campaign

Inga Odenholt, Elisabeth Löwdin, Otto Cars

The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci Keith Klugman, Fred Goldstein,

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Training for the infectious diseases speciality in Norway

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach,

Pharmacodynamic properties of HMR 3004, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time.

Cephalosporins: a pharmacological update

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections P.S. Hicks, B.

Ventilator-associated pneumonia—Understanding epidemiology and pathogenesis to guide prevention and empiric therapy Patrick Francioli, Jean Chastre,

Sepsis and neutropenia induced by clozapine

Antibiotic usage and the incidence of resistance

Uncommon opportunistic fungi: new nosocomial threats

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

André Bryskier Clinical Microbiology and Infection

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

W.A. Craig Clinical Microbiology and Infection

Recent developments in staphylococcal scalded skin syndrome

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease Inge O. Baas, G. Johan A. Offerhaus, Ralph.

G.R. Davies Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Community-acquired pneumonia: epidemiologic and clinical consideration

Reducing antibiotic use in influenza: challenges and rewards

Fibronectin concentrations in catheter sepsis

Definition of the Clinical Antibacterial Spectrum of Activity

Clinical infection services—the Leiden experience

Ethan Rubinstein, Itzhak Levy Clinical Microbiology and Infection

Statin use and clinical outcomes among pneumonia patients

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection

Clinical Microbiology and Infection

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Empiric therapy of bacterial infections in severe neutropenia

Overview of cefixime use in community-acquired infections

Sanford Chodosh Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

N. Markeas, G. Stamos, I. Paraskakis, A. Giokas, G. Pistevos

Joshua P. Metlay, Daniel E. Singer Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Fernando Baquero, John F

The future of diagnostic bacteriology

Vincent Calvez, Marc Grandadam Clinical Microbiology and Infection

Presentation transcript:

Grepafloxacin: pharmacokinetics and tissue penetration Richard Wise Clinical Microbiology and Infection Volume 4, Pages S21-S24 (March 1998) DOI: 10.1111/j.1469-0691.1998.tb00685.x Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Concentration-time curves of grepafloxacin in plasma (•) and inflammatory fluid (▴) in six healthy volunteers. Reproduced with kind permission from the American Society for Microbiology, from Child et al [2]. Clinical Microbiology and Infection 1998 4, S21-S24DOI: (10.1111/j.1469-0691.1998.tb00685.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Accumulation of quinolones in polymorphonuclear leukocytes. Based on Taira et al [10]. Clinical Microbiology and Infection 1998 4, S21-S24DOI: (10.1111/j.1469-0691.1998.tb00685.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Penetration of tissues in the respiratory tract by grepafloxacin, 400 mg/day, for 4 days. Reproduced with permission from Cook et al [11]. MIC value for Streptococcus pneumoniae taken from Pankuch et al [12]. Clinical Microbiology and Infection 1998 4, S21-S24DOI: (10.1111/j.1469-0691.1998.tb00685.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions